Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Executive Summary

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

Advertisement

Related Content

Zulresso Is Sage’s First Step In Postpartum Depression Treatment
Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Roche Makes Case For Its Oral SMA Drug Risdiplam As Filings Beckon
Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
Biogen To Launch Phase III Alzheimer’s Prevention Study
Alzheimer's Early Approval? Skepticism Over Biogen/Eisai's BAN2401 Data Clouds Chances
Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical
Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
Roche In New Phase III Bet On MorphoSys' Anti-Amyloid Agent

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124948

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel